Panacea Biotec announces listing of EmulsiPan adjuvant in CEPI Adjuvant Library

The global market for adjuvants is expected to reach over $4.8 billion by 2028 with applications across vaccines and biological therapies including oncology. Oil-in-water emulsion adjuvants like EmulsiPan are used in multiple commercial vaccines like the flu vaccines.

EmulsiPan’s open access and affordability signal Panacea Biotec’s entry into commercialisation of adjuvants. The increasing prevalence of communicable diseases and the need for effective vaccines are driving the demand for oil-in-water emulsions. It is also used in animal vaccines. EmulsiPan has been utilized in several high-impact preclinical studies and collaborative research programs.

Notably, it has been employed in non-human primate (NHP) challenge studies for Sarbecoronavirus candidate vaccine development at California Institute of Technology (Caltech), and in the Betacoronavirus candidate vaccine development program in collaboration with BRIC-Translational Health Science and Technology Institute (THSTI) and funded by CEPI.

These collaborations highlight EmulsiPan as a reliable and adaptable adjuvant platform across a diverse range of vaccine development efforts.

EmulsiPan was developed in 2009 and commercialised as part of PandyFlu (Panacea Biotec’s H1N1 vaccine). 

At that time, Panacea Biotec successfully developed the adjuvant, established a cGMP manufacturing facility, developed the vaccine, including the adjuvant, on a fast-track basis to respond to the pandemic situation. EmulsiPan does not require any licensing fees - ensuring affordability and providing open access for vaccine developers.